Open AccessNo Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy
Author(s) -
Feng HwaPing,
Guo Zifang,
Caro Luzelena,
Marshall William L.,
Liu Fang,
Panebianco Deborah,
Vaddady Pavan,
Reitmann Christina,
Jumes Patricia,
Wolford Dennis,
Fraser Iain,
Valesky Robert,
Martinho Monika,
Butterton Joan R.,
Iwamoto Marian,
Webster Lynn,
Yeh Wendy W.
Publication year - 2018
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12564
Subject(s) - methadone , medicine , pharmacokinetics , pharmacology , anesthesia
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK‐8742‐P010 and MK‐5172‐P030) in non‐hepatitis C virus (HCV)‐infected participants on methadone maintenance therapy. Coadministration of EBR or GZR with methadone had no clinically meaningful effect on EBR, GZR, or methadone pharmacokinetics. The geometric mean ratios (GMRs) for R‐ and S‐methadone AUC 0‐24 were 1.03 (90% confidence interval (CI), 0.92 – 1.15) and 1.09 (90% CI, 0.94 – 1.26) in the presence/absence of EBR; and 1.09 (90% CI, 1.02 – 1.17) and 1.23 (90% CI, 1.12 – 1.35) in the presence/absence of GZR. The GMRs for EBR and GZR AUC 0‐24 in participants receiving methadone relative to a healthy historical cohort not receiving methadone were 1.20 (90% CI, 0.94 – 1.53) and 1.03 (90% CI, 0.76 – 1.41), respectively. These results indicate that no dose adjustment is required for individuals with HCV infection receiving stable methadone therapy and the EBR/GZR fixed‐dose regimen .